Sydney, May 23, 2006 (ABN Newswire) - HeartWare (ASX: HTW) in accordance with ASX Listing Rule 3.13.3 provides a copy of the presentations which are to be delivered today at the Company's Annual General Meeting.
Overview: Heart failure is a leading cause of death in the developed world and represents a significant emerging medical device market
- HeartWare is developing a family of implantable heart pumps for the treatment of advanced heart failure
- HeartWare's HVAD, the smallest 3rd generation heart pump, is demonstrating outstanding early clinical results
- By the end of 2006, HeartWare aims to complete enrolment in its EU / Australian clinical trial and to commence its US clinical trials, subject to approvals
- HeartWare's next generation device, the MVAD, is in pre-clinical studies
- HeartWare has a strong IP portfolio and proven management capability
The Presentation is available for download at; http://htw.irmau.com/irm/Company/ShowPage.aspx?CPID=1005
The AGM is being held at the Company's auditors, Grant Thornton, at Level 17, 383 Kent Street, Sydney, commencing at 10am.
The AGM may also be viewed by webcast at the following address: http://www.streamx.com.au/heartware/agm06/start.htm
Source: HeartWare Limited Investment Centre
About HEARTWARE LIMITED
HeartWare is developing a family of proprietary circulatory assist devices to treat patients with congestive heart failure. HeartWare's lead device, the HVAD, commenced human clinical trials in March 2006. First sales are anticipated in late 2007. With a volume of 45cc, the HVAD is the smallest "3rd generation" pump and the only full output device implantable within the pericardial space.
In parallel with the HVAD clinical development, HeartWare is pursuing its MVAD program, aimed at developing a family of miniaturized cardiac assist devices, implantable by minimally invasive surgical techniques. The current MVAD prototype, approximately one tenth the volume of the HVAD, commenced animal studies in August 2005.
HeartWare listed on the Australian Stock Exchange (ASX: HTW) on 31 January 2005 after successfully raising A$32.4 million (US$24.95 million). HeartWare's Head Office is located in Sydney, Australia.
News 
